Survival in primary hemophagocytic lymphohistiocytosis 2016-2021: etoposide is better than its reputation

Svea Böhm,Katharina Wustrau,Jana Pachlopnik Schmid,Seraina Prader,Martina Ahlmann,Joanne Yacobovich,Rita Beier,Carsten Speckmann,Wolfgang Behnisch,Marianne Ifversen,Michael Jordan,Rebecca Marsh,Nora Naumann-Bartsch,Christine Mauz-Körholz,Manfred Hönig,Ansgar Schulz,Iwona Malinowska,Melissa Hines,Kim E. Nichols,Juana Gil-Herrera

Blood（2023）

引用 0|浏览8

暂无评分

摘要

F0B7Compared to historical studies, 3-year survival for patients with primary HLH improved to 77% for patients receiving first-line etoposide.F0B7Contemporary outcome of primary HLH patients is better than anticipated, providing a benchmark for evaluation of novel treatment regimens.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要